PR Newswire

ROCKVILLE, Md., Oct. 12, 2026

• Event to include clinical program overview and perspectives from leading retina specialists ahead of topline pivotal data readout anticipated in 4Q 2026

ROCKVILLE, Md. , Oct. 12, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will host an investor event at 1:00 p.m. ET on Tuesday, October 20, 2026 to review the surabgene lomparvovec (sura-vec, ABBV-RGX-314) clinical program in wet age-related macular degeneration (wet AMD) ahead of the topline pivotal data anticipated in the fourth quarter of 2026. The event will be held in-person in New York, NY and available via webcast.

Along with a clinical program overview, the event will feature perspectives from REGENXBIO management and leading retina specialists on the treatment landscape, unmet need, ATMOSPHERE ®  and ASCENT ®  pivotal trials, and commercial readiness of sura-vec in wet AMD.

Featured key opinion leaders include:

• Gaurav Shah, M.D., FASRS, California Pacific Medical Center, Sutter Health
• Arshad Khanani, M.D., MA, FASRS, Sierra Eye Associates
• Lejla Vajzovic, M.D., FASRS, Duke University School of Medicine
• Rahul Khurana, M.D., FASRS, Northern California Retina Vitreous Associates, University of California at San Francisco
• Ramanath Bhandari, M.D., FASRS, Springfield Clinic Eye Institute

Sura-vec in Wet AMD: Clinical Program Overview and Expert Perspectives
Date: Tuesday, October 20, 2026
Time: 1:00 p.m. ET – 4:00 p.m. ET
Location: New York, NY and Virtual

Registration for the webcast is available at this LINK .   

An archived replay of the webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the event.

ABOUTREGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA ® and ITVISMA ® . REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit  WWW.REGENXBIO.COM .

Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com

Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com

SOURCE REGENXBIO Inc.